Viking Therapeutics Announces Positive Phase 2 Trial Results for VK2735
On September 22, Viking Therapeutics (VKTX) announced positive top-line results from its Phase 2 trial of the dual GLP-1/GIP agonist candidate, VK2735. The study showed up to 22% placebo-adjusted weight loss at week 33 and demonstrated effective maintenance with flexible dosing schedules—every other week or monthly. These findings represent a significant de-risking milestone for Viking Therapeutics stock. The results also highlighted the drug's favorable safety profile, positioning VKTX as a potential competitor in the growing obesity treatment market dominated by drugs like Wegovy and Zepbound. Analysts remain bullish on Viking’s long-term prospects with a
Tickers: $VKTX
Topics: biotech GLP-1/GIP agonist weight loss drug development